These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 25558834)

  • 21. Dealing with the complex drug-drug interactions: towards mechanistic models.
    Varma MV; Pang KS; Isoherranen N; Zhao P
    Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
    Gomez DY; Wacher VJ; Tomlanovich SJ; Hebert MF; Benet LZ
    Clin Pharmacol Ther; 1995 Jul; 58(1):15-9. PubMed ID: 7628178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2.
    Kast RE; Altschuler EL
    Med Hypotheses; 2006; 67(6):1389-90. PubMed ID: 16893613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine.
    Kanacher T; Lindauer A; Mezzalana E; Michon I; Veau C; Mantilla JDG; Nock V; Fleury A
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33302490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction.
    Hallifax D; Houston JB
    Drug Metab Dispos; 2007 Aug; 35(8):1325-32. PubMed ID: 17470525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
    Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2011 Sep; 39(9):1633-42. PubMed ID: 21632965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.
    Labellarte M; Biederman J; Emslie G; Ferguson J; Khan A; Ruckle J; Sallee R; Riddle M
    J Am Acad Child Adolesc Psychiatry; 2004 Dec; 43(12):1497-505. PubMed ID: 15564819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
    Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
    Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models.
    Chiang CW; Zhang P; Wang X; Wang L; Zhang S; Ning X; Shen L; Quinney SK; Li L
    Clin Pharmacol Ther; 2018 Feb; 103(2):287-295. PubMed ID: 29052226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects.
    De Vries MH; Van Harten J; Van Bemmel P; Raghoebar M
    Biopharm Drug Dispos; 1993 May; 14(4):291-6. PubMed ID: 8499580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.
    Orlando R; De Martin S; Andrighetto L; Floreani M; Palatini P
    Br J Clin Pharmacol; 2010 Mar; 69(3):279-86. PubMed ID: 20233199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption.
    Jogiraju VK; Heimbach T; Toderika Y; Taft DR
    Drug Metab Pharmacokinet; 2021 Apr; 37():100375. PubMed ID: 33561738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics.
    Obach RS; Ryder TF
    Drug Metab Dispos; 2010 Aug; 38(8):1381-91. PubMed ID: 20478852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients.
    Paulzen M; Finkelmeyer A; Grözinger M
    Pharmacopsychiatry; 2011 Nov; 44(7):317-23. PubMed ID: 21979923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework.
    Zhang M; Fisher C; Gardner I; Pan X; Kilford P; Bois FY; Jamei M
    Drug Metab Dispos; 2022 Jul; 50(7):957-967. PubMed ID: 35504655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools.
    De Buck SS; Sinha VK; Fenu LA; Gilissen RA; Mackie CE; Nijsen MJ
    Drug Metab Dispos; 2007 Apr; 35(4):649-59. PubMed ID: 17267621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats.
    Krishnan K; Crouse LC; Bazar MA; Major MA; Reddy G
    J Appl Toxicol; 2009 Oct; 29(7):629-37. PubMed ID: 19629953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats.
    Fukushima K; Kobuchi S; Shibata M; Takada K; Sugioka N
    J Pharm Pharm Sci; 2011; 14(3):414-24. PubMed ID: 22202224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.